Clinical Trial

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

Study acronym: COVID-19
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-08-21; most recent amendment 2025-11-06.
Status change: Active, Not Recruiting → Recruiting 2023-11-07
Trial Details
NCT Number NCT06008860
Lead Sponsor University of Chicago
Conditions COVID-19
Enrollment 280 participants
Start Date 2023-07-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-10